InvestorRoom D http://immunepharmaceuticals.investorroom.com/ IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of CepleneĀ® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology J http://immunepharmaceuticals.investorroom.com/2017-07-05-IMMUNE-Pharmaceuticals-Oncology-Subsidiary-CYTOVIA-Announces-Additional-Clinical-Trial-Results-on-the-Efficacy-of-Ceplene-R-in-Combination-with-Low-Dose-IL-2-in-Patients-With-Acute-Myeloid-Leukemia-Recently-Published-in-Leukemia-a-Leading-Hemat Sixty-seven per cent of patients with functional natural killer (NK) cells remained disease-free at a pre-determined end point that followed two years of treatment Wed, 05 Jul 2017 08:30:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-07-05-IMMUNE-Pharmaceuticals-Oncology-Subsidiary-CYTOVIA-Announces-Additional-Clinical-Trial-Results-on-the-Efficacy-of-Ceplene-R-in-Combination-with-Low-Dose-IL-2-in-Patients-With-Acute-Myeloid-Leukemia-Recently-Published-in-Leukemia-a-Leading-Hemat Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of CepleneĀ® in Latin America http://immunepharmaceuticals.investorroom.com/2017-06-29-Immune-Pharmaceuticals-Oncology-Subsidiary-Cytovia-Inc-Provides-Update-to-Proposed-Pint-Pharma-Transaction-Substantial-Agreement-Reached-on-Material-Terms-of-the-Licensing-and-Commercialization-of-Ceplene-R-in-Latin-America Thu, 29 Jun 2017 08:30:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-29-Immune-Pharmaceuticals-Oncology-Subsidiary-Cytovia-Inc-Provides-Update-to-Proposed-Pint-Pharma-Transaction-Substantial-Agreement-Reached-on-Material-Terms-of-the-Licensing-and-Commercialization-of-Ceplene-R-in-Latin-America Immune Pharmaceuticals announces initiation of enrollment in clinical trial with CepleneĀ®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) http://immunepharmaceuticals.investorroom.com/2017-06-20-Immune-Pharmaceuticals-announces-initiation-of-enrollment-in-clinical-trial-with-Ceplene-R-low-dose-IL-2-in-Chronic-Myelomonocytic-Leukemia-CMML Immune's subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene Tue, 20 Jun 2017 09:14:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-20-Immune-Pharmaceuticals-announces-initiation-of-enrollment-in-clinical-trial-with-Ceplene-R-low-dose-IL-2-in-Chronic-Myelomonocytic-Leukemia-CMML Immune Receives NASDAQ Compliance Letter http://immunepharmaceuticals.investorroom.com/2017-06-19-Immune-Receives-NASDAQ-Compliance-Letter Mon, 19 Jun 2017 08:30:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-19-Immune-Receives-NASDAQ-Compliance-Letter Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene http://immunepharmaceuticals.investorroom.com/2017-06-15-Immune-Pharmaceuticals-Signs-Agreement-to-Regain-Worldwide-Rights-for-Ceplene Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America Thu, 15 Jun 2017 09:28:00 -0400 http://immunepharmaceuticals.investorroom.com/2017-06-15-Immune-Pharmaceuticals-Signs-Agreement-to-Regain-Worldwide-Rights-for-Ceplene